Compare
IN8BIO, Inc. vs Inmune Bio, Inc. vs Jasper Therapeutics, Inc. vs CEL SCI Corp
| Latest fiscal year | IN8BIO, Inc. INAB | Inmune Bio, Inc. INMB | Jasper Therapeutics, Inc. JSPR | CEL SCI Corp CVM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-09-30 |
| Revenue | n/a | $50.0K | n/a | n/a |
| Revenue growth (YoY) | n/a | +257.1% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$19.44M | -$45.93M | -$75.80M | -$25.41M |
| EPS (Diluted) | -$4.44 | -$1.86 | -$3.95 | -$6.27 |
| Operating cash flow | -$12.71M | -$22.58M | -$77.16M | -$17.12M |
| Free cash flow | n/a | -$23.62M | n/a | -$17.16M |
| Cash & equivalents | n/a | $24.75M | $28.69M | n/a |
| Total assets | $32.28M | $32.35M | $35.78M | $28.16M |
| Total liabilities | $4.72M | $8.83M | $31.63M | $12.20M |
| Shareholders' equity | $27.56M | $23.52M | $4.15M | $15.96M |
| Return on year-end equity | -70.5% | -195.3% | n/m | -159.2% |
| Shares outstanding | 9.77M | 26.59M | 28.00M | 8.02M |
Revenue, most recent five fiscal years
| Fiscal year | IN8BIO, Inc. | Inmune Bio, Inc. | Jasper Therapeutics, Inc. | CEL SCI Corp |
|---|---|---|---|---|
| Latest | n/a | $50.0K Ended 2025-12-31 | n/a | $264.0K Ended 2014-09-30 |
| 1 year earlier | n/a | $14.0K Ended 2024-12-31 | n/a | $159.6K Ended 2013-09-30 |
| 2 years earlier | n/a | $155.0K Ended 2023-12-31 | n/a | $254.6K Ended 2012-09-30 |
| 3 years earlier | n/a | $374.0K Ended 2022-12-31 | n/a | $956.2K Ended 2011-09-30 |
| 4 years earlier | n/a | $181.0K Ended 2021-12-31 | n/a | n/a |